Traditional surgical open-heart surgery is the mainstay of treatment for precordial disease. The success rate of surgical procedures for simple malformations is close to 100%. However, surgical procedures require open chest, or f and) extracorporeal cardiopulmonary diversion, which is highly invasive, has a long postoperative recovery time, and brings about surgical complications and leaves surgical scars that cause long-lasting physical and psychological trauma to the patient. In addition, there is a certain rate of recanalization after surgery for patent ductus arteriosus (PDA) and atrial septal defect (ASD) and ventricular septal defect (VSD), some of which require reoperation. Certain complication rates and cosmetic problems associated with surgical procedures have caused attempts to replace surgical treatment with minimally invasive interventional methods. In recent years, interventional treatment of congenital heart disease has been greatly promoted with the development of interventional materials and improvement of interventional techniques, especially in 1997 when Amplatz developed a new generation of blockers for clinical congenital heart disease. The scope of indications for the treatment of congenital heart disease has been expanding and the number of treatments has been rapidly increasing due to the improved operation techniques, simple and safe operation procedures, as well as the advantages of less trauma without surgical scars, no blood transfusion and short hospital stay. At present, the scope of treatment includes not only common precardiac diseases such as ventricular septal defect, atrial septal defect, patent ductus arteriosus, pulmonary valve stenosis, but also rare precardiac diseases such as aortic constriction, aortic stenosis, pulmonary arteriovenous fistula, coronary arteriovenous fistula and medical-surgical mosaic treatment of complex precardiac diseases. It is foreseen that there will be a major shift in the treatment of precardiac diseases, first of all, the interventional treatment of precardiac diseases will also tend to be more age-specific. The optimal age for treatment of precardiac disease is clear based on its hemodynamic characteristics. In the past, due to the economic backwardness of our country, a considerable proportion of adults with precardiac disease were not treated in time, but the situation will gradually change, and in the near future pediatric interventions for precardiac disease will become the mainstay. Secondly, the treatment strategy of precardiac disease has changed – most of the treatment of single and compound malformations of precardiac disease will be replaced by transcatheter interventions. In contrast, complex malformations will change from a single surgical approach in the past to one that can be accomplished through transcatheter interventions in conjunction with surgical procedures. On the other hand, transcatheter valve placement will have a breakthrough, the most promising is the artificial valve stent, the use of biological valve (porcine valve, pericardial valve) sewn to self-expanding stent placement into the aorta or pulmonary artery has been successful, and will be gradually applied to the clinical. The new technology, new equipment and the localization of implantation devices will further reduce the medical costs of patients and solve the problem of expensive medical care, while also simplifying the operation techniques and providing personalized treatment.